143 related articles for article (PubMed ID: 1971598)
1. Illustration of the effects of long-term xamoterol therapy on the time course of left ventricular pressure.
van Mechelen H; Ries A; Pouleur H; Rousseau MF
Eur Heart J; 1990 Apr; 11 Suppl A():67-9. PubMed ID: 1971598
[TBL] [Abstract][Full Text] [Related]
2. Clinical experience of therapy with xamoterol in patients with severe systolic and diastolic dysfunction.
Pouleur H; Hanet C; Rousseau MF
Eur Heart J; 1990 Apr; 11 Suppl A():33-8. PubMed ID: 1971587
[TBL] [Abstract][Full Text] [Related]
3. Beta, partial agonists to treat heart failure: effects of xamoterol upon cardiac function and clinical status.
Heng MK
Clin Cardiol; 1990 Mar; 13(3):171-6. PubMed ID: 1969783
[TBL] [Abstract][Full Text] [Related]
4. [Role of adrenergic beta receptor partial agonists in left ventricular failure of ischemic origin. Value of xamoterol (ICI 118,587, Corwin)].
Rousseau MF; Cheron P; Nannan M; Vincent MF; Lavenne F; Pouleur H
Ann Med Interne (Paris); 1985; 136(3):247-50. PubMed ID: 2862823
[TBL] [Abstract][Full Text] [Related]
5. Effects of xamoterol on resting and exercise haemodynamics in patients with chronic heart failure.
Virk SJ; Davies MK
Br J Clin Pharmacol; 1989; 28 Suppl 1(Suppl 1):15S-22S. PubMed ID: 2572250
[TBL] [Abstract][Full Text] [Related]
6. Long-term effects of xamoterol on left ventricular diastolic function and late remodeling: a study in patients with anterior myocardial infarction and single-vessel disease.
Pouleur H; van Eyll C; Hanet C; Cheron P; Charlier AA; Rousseau MF
Circulation; 1988 May; 77(5):1081-9. PubMed ID: 2896076
[TBL] [Abstract][Full Text] [Related]
7. Effects of the beta 1-adrenergic receptor partial agonist xamoterol on left ventricular diastolic function. An evaluation after 1-6 years of oral therapy.
Pouleur H; Etienne J; Van Mechelen H; Gurné O; Rousseau MF
Circulation; 1990 Feb; 81(2 Suppl):III87-92. PubMed ID: 1967560
[TBL] [Abstract][Full Text] [Related]
8. Contrasting effects of single doses of pindolol and xamoterol on left ventricular diastolic function.
Rousseau MF; Pouleur H; Debaisieux JC; Van Eyll C; Charlier AA
Br J Clin Pharmacol; 1989; 28 Suppl 1(Suppl 1):84S-85S. PubMed ID: 2572264
[TBL] [Abstract][Full Text] [Related]
9. Xamoterol and the failing heart.
Davies MK
Lancet; 1990 Jan; 335(8681):117-8. PubMed ID: 1967408
[No Abstract] [Full Text] [Related]
10. Effect of xamoterol on myocardial energetics in man.
Sakai O; Fujita M; Sasayama S; Asanoi H; Nakajima H; Yokawa S
Jpn Circ J; 1988 Feb; 52(2):149-54. PubMed ID: 2896256
[TBL] [Abstract][Full Text] [Related]
11. Echocardiographic assessment of lack of beta 1-receptor down-regulation during prolonged therapy with xamoterol.
Cheron P; Nannan M; Pouleur H; Rousseau MF
Eur Heart J; 1990 Apr; 11 Suppl A():46-7. PubMed ID: 1971589
[TBL] [Abstract][Full Text] [Related]
12. Effects of long-term xamoterol therapy on the left ventricular mechanical efficiency in patients with ischemic heart disease.
Pouleur H; van Eyll C; Etienne J; van Mechelen H; Vuylsteke A; Rousseau MF
Basic Res Cardiol; 1989; 84 Suppl 1():157-62. PubMed ID: 2573338
[TBL] [Abstract][Full Text] [Related]
13. Improvement of left ventricular contractility and relaxation with the beta 1-adrenergic receptor partial agonist xamoterol at rest and during exercise in patients with postinfarction left ventricular dysfunction. A placebo-controlled randomized trial.
de Feyter PJ; Serruys PW; Suryapranata H
Circulation; 1990 Feb; 81(2 Suppl):III99-106. PubMed ID: 1967562
[TBL] [Abstract][Full Text] [Related]
14. Effects of xamoterol in acute myocardial infarction: blood pressure, heart rate, arrhythmias and early clinical course.
McMurray J; Lang CC; MacLean D; Struthers AD; McDevitt DG
Int J Cardiol; 1991 Jun; 31(3):295-303. PubMed ID: 1679047
[TBL] [Abstract][Full Text] [Related]
15. Sympathetic modulation in practice: the German clinical experience.
Kupper W; Erlemeier HH; Bleifeld W
Eur Heart J; 1990 Apr; 11 Suppl A():19-25. PubMed ID: 1971586
[TBL] [Abstract][Full Text] [Related]
16. Immediate central and regional haemodynamic effects of a new beta 1-adrenergic stimulating drug, xamoterol (Corwin) in healthy volunteers.
Tangø M; Carlsen JE; Trap-Jensen J
Eur J Clin Pharmacol; 1985; 29(2):155-8. PubMed ID: 2866963
[TBL] [Abstract][Full Text] [Related]
17. The pharmacology of xamoterol: a basis for modulation of the autonomic control of the heart.
Snow HM
Br J Clin Pharmacol; 1989; 28 Suppl 1(Suppl 1):3S-13S. PubMed ID: 2572252
[TBL] [Abstract][Full Text] [Related]
18. Comparative effects of dobutamine and corwin, a beta 1-adrenergic partial agonist, in experimental left ventricular failure.
Vik-Mo H; Yasay G; Maroko PR; Ribeiro LG
J Cardiovasc Pharmacol; 1985; 7(4):784-90. PubMed ID: 2410722
[TBL] [Abstract][Full Text] [Related]
19. Comparisons of the inotropic effects of the beta 1-adrenoceptor partial agonists SL 75.177.10 and ICI 118,587 with digoxin on the intact canine heart.
Pouleur H; Van Mechelen H; Balasim H; Rousseau MF; Charlier AA
J Cardiovasc Pharmacol; 1984; 6(4):720-6. PubMed ID: 6206332
[TBL] [Abstract][Full Text] [Related]
20. Effects of xamoterol, a beta 1 adrenoceptor partial agonist, in patients with ischaemic dysfunction of the left ventricle.
Vigholt-Sørensen E; Faergeman O; Snow HM
Br Heart J; 1989 Nov; 62(5):335-41. PubMed ID: 2574049
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
